AIDS Treatment News - 1997

• AIDS Treatment News - 1997
• Issue #262
• Hundreds Turned Away from National Retroviruses Conference in January
• Retroviruses Conference: Daily CME Reports Available on World Wide Web
• AIDS Conference Information on the Internet -- How to Present It
• San Francisco: Vocational Counseling Workshops


• Issue #263
• 1997 Outlook
• Nelfinavir: Agouron Announces Expanded Access for Children, a Major New Trial, and Enlarged Expanded Access for Adults
• Retroviruses Conference: Where to Find Reporting on the Internet
• Medical Marijuana: Unpublished Federal Study Found THC- Treated Rats Lived Longer, Had Less Cancer
• Activist Groups and PWA Coalitions, U.S. and Canada


• Issue #264
• Retroviruses Conference Overview: Consolidating the Advances
• Retroviruses Conference: Where to Get Information
• Low Vitamin B-12 Blood Levels Associated with Faster Progression to AIDS
• GS 840 (Adefovir Dipivoxil): Broad-Spectrum Antiviral Trial, CD4 Count Under 100
• Opportunistic Infections: Major Report Available
• Acyclovir-Resistant Herpes: Expanded Access Available for Cidofovir Gel (FORVADE(TM))
• Protease Inhibitor Failures: Call for Information
• Non-Approved Liver Treatments: Call for Information
• Retroviruses Conference Excludes People with AIDS, Researchers, Physicians


• Issue #265
• Fewer AIDS Deaths and Illnesses: New Information
• Nelfinavir - Major Trial Results at Retroviruses Conference
• DANGER: Possibly Fatal Interactions Between Ritonavir and "Ecstasy," Some Other Psychoactive Drugs
• Free Viral Load Tests Becoming Available for Uninsured Patients
• ABT-378: Abbott "Second Generation" Protease Inhibitor
• Drug-Related Neuropathy: Low Acetylcarnitine Levels Found
• San Francisco: 9th National AIDS Update Conference, March 18-22
• New York: "Management of the HIV-Infected Patient," March 7-9
• New York: ACT UP 10-Year Anniversary -- Activist Conference Mar. 22-23, Wall Street Demo March 24
• Retroviruses Conference Information: Tape Sales; Email Access
• Medical Marijuana: New Nationwide Poll Shows 2-1 Public Support
• Medical Marijuana: Followup on THC Toxicology Report


• Issue #266
• Stanford NAC Study: Glutathione Level Predicts Survival
• Glutathione-Depleting Drugs: Petition to the FDA
• AIDS Survival: First Drop in Total Deaths in U.S.; Larger Drop in France
• Protease Inhibitors: Major Study Stopped When 3-Drug Arm Proves Superior
• Help Wanted: GMHC Treatment Education Director
• San Francisco: Cattle Grazing, Reservoirs, and Cryptosporidiosis


• Issue #267
• Nelfinavir (VIRACEPT«) Approved: Fourth Protease Inhibitor Available
• Ritonavir: New Approval for Children
• HIV InSite: University of California AIDS Web Site
• Acetylcarnitine: Call for Information
• SPV-30: FDA Stops Distribution Over Advertising
• It's Time to Approve More Surrogate Markers
• AIDS Treatment Activism: Focus on Service


• Issue #268
• New AmFAR Directory: Best Quick Reference for Mainstream Treatments
• NAC, Glutamine, and Alpha Lipoic Acid
• Costa Rican PWAs Seek Treatment Access - No Success in Roche Negotiations
• Action Alert: Coburn Bill
• AIDSWATCH '97: Advocacy in Washington, April 13-15
• San Francisco Help Wanted: Outreach to Minorities, Women for AIDS Trials


• Issue #269
• Delavirdine (Rescriptor«) Approved
• Nelfinavir Combination Therapy: Ten-Month Report
• PMPA -- First Human Results
• Standard Treatments for HIV, Spring 1997
• ADAP Drug-Assistance Programs -- Funding Projections for 1998
• Medicaid: Vice President Gore Supports Early Treatment
• Medical Marijuana Wins Temporary Restraining Order
• AIDS/HIV TREATMENT DIRECTORY -- Mailing Address
• Meetings Calendar for May 1997


• Issue #270
• CMV, RS-79070: Community Concern As Major Drug's Development Suspended
• CMV Retinitis, Newly Diagnosed: RS-79070 Trial in Atlanta, Austin, Boston, Durham, Houston, Irvine, Los Angeles(?), Miami
• FDA Community Meeting May 16: Clinical Trials and Viral Load
• HIV Vaccines Need to Be Developed: Interview with Sam Avrett, International AIDS Vaccine Initiative
• 1st National AIDS Malignancy Conference -- Online Summaries Available from April 28-30 Meeting
• Medicaid -- AIDS Impact of Proposed Cuts
• Medical Marijuana: Questions Raised on San Francisco Raid


• Issue #271
• AIDS TREATMENT NEWS Needs Your Support
• Clinical Trials and Viral Load: Statement for FDA Community Meeting May 16
• 1592: Small Distribution Programs Begin June, July
• Indinavir (Crixivan(R)) Becoming Available at Many Pharmacies
• AIDS Internet: Treatment Information Online Introduction to a Series
• AIDS News on the World Wide Web: AEGIS (http://www.aegis.com) and Others
• Help Wanted: Project Inform Seeks Hotline Manager
• California: ADAP Program Adds Cidofovir, Nevirapine, and Nelfinavir
• California: Seventh Annual AIDS Lobby Day, June 2
• San Francisco: Lark Lands, Other Experts to Speak on Nutrition, Lean Body Mass, and Wasting, June 14


• Issue #272
• Limited Immune Recovery After Treatment with Antiretrovirals, IL-2; Interview with Clifford Lane, M.D.
• Viral Load in Clinical Trials: FDA Advisory Committee Meeting July 14-15
• Meetings Calendar, June 1997 - 1998


• Issue #273
• FDA Explores New Antiretroviral Trial Designs: Interview with David Feigal, M.D.
• Protease Inhibitors: FDA Warns Doctors of Diabetes Risk
• 1592: Protests on Small Access Program
• Help Wanted, Wash. D.C.:
• San Francisco, Oakland: Treatment Access Workshop, June 27, July 11, and July 18


• Issue #274
• New Standard of Care for HIV Disease
• Major Pediatric Study Stopped Early: Combination Treatment Better
• Saquinavir: Major Study Shows Survival Benefit in Treatment-Naive Patients
• HIV Resistance International Meeting: Summary on Web; Half-Day Meetings in San Francisco and New York
• National Summit Meeting on HIV Resistance, July 17 -- By Telephone
• AmFAR Will End Support of CBCT Network, Begin New Clinical Program
• Internet Free Speech Upheld
• AIDS CARE Newsletter
• San Francisco, Healing Alternatives: Help Wanted, Also Directors, Volunteers
• California: AIDS Hotline Expands to Cover State, Increases Hours


• Issue #275
• Health Insurance More Available: Federal Legislation Effective July 1
• Pediatric Trial of 141W94, Vertex Protease Inhibitor
• Pediatric 1592 Compassionate Use Program Begins
• World Wide Web AIDS Medical Information


• Issue #276
• 1592 Adult Compassionate-Use Program Announced
• Returning to Work: Articles on Social Security Rules
• Federal AIDS Policy Issues Today


• Issue #277
• Protease Inhibitors' Metabolic Side Effects: Cholesterol, Triglycerides, Blood Sugar, and "Crix Belly." Interview with Li
• Taxol Approved for Kaposi's Sarcoma
• San Francisco: Changes at Conant Medical Group
• IDSA Annual Meeting, September 12-16, San Francisco
• 1998 Retroviruses Conference: Deadlines Available Soon
• AIDS Treatment News Must Increase Prices
• Consensus Letter: Peter Duesberg


• Issue #278
• HMOs and Quality Care for HIV -- Interview with Stephen Becker,M.D. (Part 1 of 2)
• Retroviruses Conference Deadlines: Community Press,Scholarships,Nov. 3; Abstracts October 3, Late-Breakers January 5
• DMP 266 Trials Recruiting, Many Cities -- Protease Inhibitor Naive
• Adefovir Dipivoxil Trials: CD4 100-500, Protease Inhibitor Naive
• Activism: * Internet Training; * San Francisco Workshop; * Needle Exchange Sept. 17; * California Prison HIV Care
• Virologic Failure; Managed Care; Treatment Rejectionists; Medical Research: GLMA Achievement Award


• Issue #279
• Engineered Virus Targets HIV-Infected Cells: Interview with Garry Nolan, Ph.D.
• Efavirenz (SUSTIVA [tm]) Expanded Access Begins October 1
• Efavirenz (SUSTIVA [tm]), Formerly DMP-266) 48-Week Data Announced
• T-20: Entirely New Antiretroviral
• IDSA '97: Conference Without Activists
• IDSA '97: What It Did Right
• IDSA '97: Excellent Medical Summaries on Tape


• Issue #280
• Fifty Volunteer for Live-Vaccine Trial
• 37th ICAAC Conference, Toronto, Sept. 28 - Oct. 1
• Unused Drugs Sought for Donation Abroad
• Pregnant Women Eligible for Single-Dose Nevirapine Study
• ADAP, Research, and Prevention Funding, and Needle Exchange, Facing Decisions Now: Your Calls Important
• "Poppers"--Annotated Reference List Available
• HMOs and Quality Care for HIV -- Interview with Stephen Becker, M.D. (Part 2 of 2)


• Issue #281
• Long-Term Strategies: Should Some Patients Wait to Start Protease Inhibitors? Interview with Keith Henry, M.D.
• ICAAC Newspaper Headlines Misleading on Protease Inhibitor Failure
• ICAAC: Online Summaries Available
• Delavirdine Combination and Viral Load
• Linezolid, New Antibiotic Studied for MRSA, Available for Compassionate Use
• International Conference on AIDS Wasting, Nov. 16-19, Fort Lauderdale, Florida
• Telephone Conference on Resistance and Cross-Resistance, Nov. 5, 1997
• Telephone Conference on HIV Treatment Developments, Oct. 30
• Money, Foundations, and the Public Agenda: Investigative Articles Available


• Issue #282
• HIV Research Overview: Interview with David Ho, M.D.
• Expanded Access to Experimental Drugs: Activists Seek More Open Programs
• AIDS Dementia: 1592 Now More Available
• Qigong Exercise Program Airing in Los Angeles Area; Tape Available
• Correction: ICAAC Location
• AIDS Service Organizations: Accountability Issue Surfaces in San Francisco


• Issue #283
• FORTOVASE (tm) Approved: New Saquinavir Formulation
• 1592 Access: Larger Program Planned
• HIV Resistance Testing: More Questions Than Answers
• Drug-Resistant Herpes: Cidofovir Gel in Limbo. Interview with Jay Lalezari, M.D.
• Treatment in Developing Countries: New UNAIDS Pilot Program
• Geneva Conference Deadlines: Time to Start Planning


• Issue #284
• Viral Immunology Advances Suggest Treatment Strategies
• New Meeting on Immune Surrogate Markers, Baltimore, January 9-11
• FDA Approves New Kind of Lymphoma Treatment
• Major AIDS Institute Inaugurated in San Francisco
• Protease Inhibitor Information: FDA Fact Sheet Available
• Protease Inhibitor Failure Trial: Combination 1592, 141W94, and Efavirenz
• New AIDS Bookstore on World Wide Web
• Revised Federal Antiretroviral Treatment Guidelines
• FDA Reform Signed into Law
• Press Must Register Now to Cover Feb. Retroviruses Meeting; Dec. 29 Deadline
• Correction: FORTOVASE(tm) Information Number for Patients in Wash. D.C. Area
• December Deadline for Charitable Giving and Tax Relief


• Issue #285
• New Approaches to HIV Treatment: Interview with Robert Gallo, M.D.
• 1592 (Abacavir): Do Not Rechallenge After Hypersensitivity Reaction
• Adefovir Dipivoxil (PREVEON (tm) ) Expanded Access Begins
• San Francisco: Eviction Legislation Protects Some with Major Illness
• New York: One-Day Treatment Information Forum, January 17
• AIDS Treatment News Index, 1997

All information on AIDS.ORG is designed to support, but not replace your relationship with your doctor, and is intended soley for educational or research purposes. Any and all personal information you may provide us with is never released to anyone at any time. Your privacy and trust is extremely important to us.

• News
• Topics
• Experience
• Donate
• About Us

• Headlines
• AIDS Treatment News